Key Details
Price
$468.08Annual ROE
80.74%Beta
0.97Events Calendar
Next earnings date:
May 01, 2025Recent quarterly earnings:
Feb 03, 2025Recent annual earnings:
Feb 03, 2025Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
June 16, 2015Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
On Monday, February 3, the S&P 500 dropped by 0.8% as investors responded to tariffs affecting important U.S. trading partners and looked forward to important earnings and job market information.
U.S. stocks fell in the middle of the day, but they recovered slightly after President Trump decided to delay new tariffs on Mexico.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) will hold its Q4 2024 Earnings Conference Call on February 3, 2025, at 8:30 AM ET. The call will feature company representatives including Brian McKeon, Andrew Emerson, and Jay Mazelsky. Participants from various financial institutions will also join the discussion.
IDEXX Laboratories (IDXX) saw its shares rise by 10% on Monday, making it the top gainer in the S&P 500. This increase followed the company's announcement of stronger-than-expected demand for its animal testing products and higher prices.
Idexx Laboratories, a company that specializes in veterinary diagnostics, announced its fourth-quarter earnings on Monday, February 3. Their revenue reached $954 million, which was higher than the anticipated $935 million, exceeding analysts' expectations for both revenue and profits.
Idexx Laboratories (IDXX) reported quarterly earnings of $2.62 per share, which is higher than the Zacks Consensus Estimate of $2.40 per share. This is an increase compared to last year's earnings of $2.32 per share.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a worldwide leader in pet healthcare advancements, has released its results for the fourth quarter and the entire year. Jay Mazelsky, President and CEO, stated that IDEXX had a strong end to 2024, thanks to the excellent performance of its teams around the world. The company is at the beginning of a new era of significant innovation, having started to ship the IDEXX inVue Dx™ Cellular Analyzer in Q4.
IDEXX Laboratories is likely to have performed well in the fourth quarter of 2024 due to effective implementation of its key strategies.
IDEXX has introduced a new cancer diagnostic panel that includes a test for the early detection of canine lymphoma.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a top company in pet healthcare innovation, will announce its financial results for the fourth quarter and full year of 2024 on Monday, February 3, 2025, before the market opens. An analyst conference call will take place at 8:30 a.m. ET on that day. People can listen to the live webcast of the call, read the prepared remarks, and view the Q4 2024 Earnings Snapshot via a provided link.
FAQ
- What is the primary business of IDEXX Laboratories?
- What is the ticker symbol for IDEXX Laboratories?
- Does IDEXX Laboratories pay dividends?
- What sector is IDEXX Laboratories in?
- What industry is IDEXX Laboratories in?
- What country is IDEXX Laboratories based in?
- When did IDEXX Laboratories go public?
- Is IDEXX Laboratories in the S&P 500?
- Is IDEXX Laboratories in the NASDAQ 100?
- Is IDEXX Laboratories in the Dow Jones?
- When was IDEXX Laboratories's last earnings report?
- When does IDEXX Laboratories report earnings?
- Should I buy IDEXX Laboratories stock now?